255 related articles for article (PubMed ID: 25102355)
1. Short-term protection conferred by Leishvacin® against experimental Leishmania amazonensis infection in C57BL/6 mice.
Carneiro MB; de Andrade e Sousa LM; Vaz LG; Dos Santos LM; Vilela L; de Souza CC; Gonçalves R; Tafuri WL; Afonso LC; Côrtes DF; Vieira LQ
Parasitol Int; 2014 Dec; 63(6):826-34. PubMed ID: 25102355
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice.
Pratti JE; Ramos TD; Pereira JC; da Fonseca-Martins AM; Maciel-Oliveira D; Oliveira-Silva G; de Mello MF; Chaves SP; Gomes DC; Diaz BL; Rossi-Bergmann B; de Matos Guedes HL
Parasit Vectors; 2016 Oct; 9(1):534. PubMed ID: 27716449
[TBL] [Abstract][Full Text] [Related]
4. CD8+ T cells are not required for vaccine-induced immunity against Leishmania amazonensis in IL-12/23P40(-/-) C57BL/6 mice.
Hernández Sanabria MX; Afonso LC; Golgher D; Tafuri WL; Vieira LQ
Microbes Infect; 2007 Jul; 9(9):1124-34. PubMed ID: 17662634
[TBL] [Abstract][Full Text] [Related]
5. The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy.
Pratti JES; da Fonseca Martins AM; da Silva JP; Ramos TD; Pereira JC; Firmino-Cruz L; Oliveira-Maciel D; Vieira TSS; Lacerda LL; Vale AM; Freire-de-Lima CG; Gomes DCO; Saraiva EM; Rossi-Bergmann B; de Matos Guedes HL
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007146. PubMed ID: 30802247
[TBL] [Abstract][Full Text] [Related]
6. Platelet activating factor receptor-deficient mice present delayed interferon-gamma upregulation and high susceptibility to Leishmania amazonensis infection.
Santiago HC; Braga Pires MF; Souza DG; Roffê E; Côrtes DF; Tafuri WL; Teixeira MM; Vieira LQ
Microbes Infect; 2006 Sep; 8(11):2569-77. PubMed ID: 16938478
[TBL] [Abstract][Full Text] [Related]
7. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
[TBL] [Abstract][Full Text] [Related]
8. Analysis of iron superoxide dismutase-encoding DNA vaccine on the evolution of the Leishmania amazonensis experimental infection.
Campos BL; Silva TN; Ribeiro SP; Carvalho KI; Kallás EG; Laurenti MD; Passero LF
Parasite Immunol; 2015 Aug; 37(8):407-16. PubMed ID: 26040192
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
10. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
[TBL] [Abstract][Full Text] [Related]
13. Identification and purification of immunogenic proteins from nonliving promastigote polyvalent Leishmania vaccine (Leishvacin ).
Cardoso SR; da Silva JC; da Costa RT; Mayrink W; Melo MN; Michalick MS; Liu IA; Fujiwara RT; Nascimento E
Rev Soc Bras Med Trop; 2003; 36(2):193-9. PubMed ID: 12806454
[TBL] [Abstract][Full Text] [Related]
14. Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production.
Grenfell RF; Marques-da-Silva EA; Souza-Testasicca MC; Coelho EA; Fernandes AP; Afonso LC; Rezende SA
Mem Inst Oswaldo Cruz; 2010 Sep; 105(6):818-22. PubMed ID: 20944999
[TBL] [Abstract][Full Text] [Related]
15. In situ cytokines (IL-4, IL-10, IL-12, IFN-γ) and chemokines (MCP-1, MIP-1α) gene expression in human Leishmania (Leishmania) Mexicana infection.
Valencia-Pacheco G; Loría-Cervera EN; Sosa-Bibiano EI; Canché-Pool EB; Vargas-Gonzalez A; Melby PC; Andrade-Narvaez FJ
Cytokine; 2014 Sep; 69(1):56-61. PubMed ID: 25022962
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
[TBL] [Abstract][Full Text] [Related]
18. Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.
Katebi A; Gholami E; Taheri T; Zahedifard F; Habibzadeh S; Taslimi Y; Shokri F; Papadopoulou B; Kamhawi S; Valenzuela JG; Rafati S
Mol Immunol; 2015 Oct; 67(2 Pt B):501-11. PubMed ID: 26298575
[TBL] [Abstract][Full Text] [Related]
19. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
